^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MK-0482

i
Other names: MK-0482
Associations
Company:
Merck (MSD)
Drug class:
ILT-3 inhibitor
Associations
1m
Enrollment open • Metastases
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402) • ifinatamab deruxtecan (DS-7300) • vibostolimab (MK-7684) • MK-0482 • MK-4830
2ms
Phase classification • Metastases
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402) • ifinatamab deruxtecan (DS-7300) • vibostolimab (MK-7684) • MK-0482 • MK-4830
6ms
New P1 trial
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD163 (CD163 Molecule) • GZMB (Granzyme B)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
8ms
Phase classification • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
9ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab (MK-7684) • MK-0482 • MK-4830
11ms
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1, N=12, Terminated, Merck Sharp & Dohme LLC | N=35 --> 12 | Active, not recruiting --> Terminated; Business Reasons
Enrollment change • Trial termination
|
MK-0482
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
12ms
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1, N=35, Active, not recruiting, Merck Sharp & Dohme LLC | Phase classification: P1b --> P1 | Trial completion date: Aug 2025 --> Dec 2023 | Trial primary completion date: Aug 2025 --> Dec 2023
Phase classification • Trial completion date • Trial primary completion date
|
MK-0482
1year
Enrollment closed • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • vibostolimab (MK-7684) • MK-0482 • MK-4830
1year
Enrollment closed • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
over1year
Enrollment closed • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
over1year
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov)
P1b, N=35, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025
Trial completion date • Trial primary completion date
|
MK-0482
almost2years
Enrollment change
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
over2years
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1b, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
over2years
Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
over2years
Enrollment change
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • 5-fluorouracil • MK-0482 • MK-4830 • dazostinag (TAK-676)
almost3years
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
over3years
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
P1, N=36, Recruiting, Presage Biosciences | Not yet recruiting --> Recruiting | N=12 --> 36 | Initiation date: Feb 2021 --> Jun 2021
Clinical • Enrollment open • Enrollment change • Trial initiation date
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)
over3years
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
P1b, N=230, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Aug 2022 --> Jun 2024 | Trial primary completion date: Aug 2022 --> Jun 2024
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
over3years
Clinical • Enrollment change • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
almost4years
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Presage Biosciences | Trial completion date: Dec 2030 --> Dec 2031 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Dec 2030 --> Dec 2031
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)
4years
Clinical • New P1 trial • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • relatlimab (BMS-986016) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676)